| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_2ef8907f6c11525e7507a0a2408187c2 |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2236-333
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2236-51
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2236-39
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2236-55 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K36-638
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K45-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P13-08
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K36-28 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K45-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P13-08
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K36-638 |
| filingDate |
2019-10-28-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_493ad979e5cfe4a0bf99e14e3ced0d48
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_8867f08f5fa9de24c7dce20266cc7e6d
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_3e2ebed576f37cf80127378c1d897e2a
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_21f9c2e815ece06eeb506c1afe27cf71
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_91fc8ec8bcc922c99abc8c31f1be28fd
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_b74da900347042f6b3cff56aeabd1399
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_2f286cd9c1d9f9c7c4b9482795f5ae57
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_1ab720ce261eb89e923791e05eac116c |
| publicationDate |
2019-12-27-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
CN-110613851-A |
| titleOfInvention |
Application of Erzhi Fang in the preparation of medicines for preventing and treating benign prostatic hyperplasia |
| abstract |
The invention belongs to the field of traditional Chinese medicine and relates to the use of Erzhi Fang in the preparation of medicines for preventing and treating benign prostatic hyperplasia. Specifically, the present invention relates to the use of a composition comprising Ligustrum lucidum and Eclipta chinensis or an extract of the composition in the preparation of a medicament selected from: (1) a medicament for treating and/or preventing benign prostatic hyperplasia; (2) Drugs for inhibiting the proliferation of human prostatic hyperplasia epithelial cells; or (3) Drugs for inhibiting PCNA protein expression and/or inhibiting its mRNA expression. The present invention also relates to an extract. The composition comprising Ligustrum lucidum and Eclipta chinensis or the extract of the composition can effectively treat and/or prevent benign prostatic hyperplasia. |
| priorityDate |
2019-10-28-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |